TY - JOUR
T1 - NAD(P)H oxidase activation
T2 - A potential target mechanism for diabetic vascular complications, progressive β-cell dysfunction and metabolic syndrome
AU - Inoguchi, Toyoshi
AU - Nawata, Hajime
PY - 2005/6
Y1 - 2005/6
N2 - Both protein kinase C (PKC) activation and increased oxidative stress have been paid attention to as important causative factors for diabetic vascular complications. In this article, we show a PKC-dependent increase in oxidative stress in vascular tissues of diabetes and insulin resistant state. High glucose level and free fatty acids stimulate de novo diacylglycerol (DAG)-PKC pathway and subsequently stimulate reactive oxygen species (ROS) production through a PKC-dependent activation of NAD(P)H oxidase. Increasing evidence has also shown that NAD(P)H oxidase components are upregulated in micro- and macro- vascular tissues of animal models and patients of diabetes and obesity. It is also noted that increased intrinsic angiotensin II production may amplify such a PKC-dependent activation of NAD(P)H oxidase in diabetic vascular tissues. These mechanisms may play an important role in the diabetic vascular complications and the accelerated atherosclerosis associated with diabetes and obesity. In addition, recent reports have shown that NAD(P)H oxidases exist in pancreatic β-cells and adipocytes, and this oxidase-generated ROS production may play an important role in both the progressive β-cell dysfunction and the dysregulated adipocytokine production and subsequent obesity-induced metabolic syndrome. These results suggest that an NAD(P)H oxidase activation may be a useful therapeutic target for preventing diabetic vascular complications, progressive β-cell dysfunction and metabolic syndrome.
AB - Both protein kinase C (PKC) activation and increased oxidative stress have been paid attention to as important causative factors for diabetic vascular complications. In this article, we show a PKC-dependent increase in oxidative stress in vascular tissues of diabetes and insulin resistant state. High glucose level and free fatty acids stimulate de novo diacylglycerol (DAG)-PKC pathway and subsequently stimulate reactive oxygen species (ROS) production through a PKC-dependent activation of NAD(P)H oxidase. Increasing evidence has also shown that NAD(P)H oxidase components are upregulated in micro- and macro- vascular tissues of animal models and patients of diabetes and obesity. It is also noted that increased intrinsic angiotensin II production may amplify such a PKC-dependent activation of NAD(P)H oxidase in diabetic vascular tissues. These mechanisms may play an important role in the diabetic vascular complications and the accelerated atherosclerosis associated with diabetes and obesity. In addition, recent reports have shown that NAD(P)H oxidases exist in pancreatic β-cells and adipocytes, and this oxidase-generated ROS production may play an important role in both the progressive β-cell dysfunction and the dysregulated adipocytokine production and subsequent obesity-induced metabolic syndrome. These results suggest that an NAD(P)H oxidase activation may be a useful therapeutic target for preventing diabetic vascular complications, progressive β-cell dysfunction and metabolic syndrome.
UR - http://www.scopus.com/inward/record.url?scp=21444439103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=21444439103&partnerID=8YFLogxK
U2 - 10.2174/1389450054021927
DO - 10.2174/1389450054021927
M3 - Review article
C2 - 16026268
AN - SCOPUS:21444439103
SN - 1389-4501
VL - 6
SP - 495
EP - 501
JO - Current Drug Targets
JF - Current Drug Targets
IS - 4
ER -